Thomas Lehrnbecher | Medicine | Best Researcher Award

Published on by Academic Excellence

Prof. Dr. Thomas Lehrnbecher | Medicine | Best Researcher Award

Prof. Dr. Thomas Lehrnbecher | Medicine | Goethe Universität Frankfurt | Germany

Dr. Thomas Lehrnbecher is a distinguished pediatric oncologist and hematologist, serving as Head of the Division of Pediatric Hematology and Oncology at Johann Wolfgang Goethe University, Frankfurt. With decades of experience, his clinical and research expertise lies in infections in immunocompromised pediatric patients, supportive care, and innovative therapeutic strategies for childhood cancers. His career spans leading roles in Germany and international collaborations at the National Cancer Institute, USA, where he trained as a post-doctoral fellow. A prolific researcher, he has published extensively in high-impact journals, shaping global practices in infection management and antifungal prophylaxis in children with cancer. Dr. Lehrnbecher has also contributed significantly to medical societies, committees, and working groups, reflecting his leadership in advancing pediatric oncology. Recognized with prestigious awards, he continues to drive progress in medicine through innovative research, clinical care, and mentorship, making him an influential figure in pediatric hematology and oncology worldwide.

Author profile 

Orcid

Education

Dr. Lehrnbecher’s medical training reflects a strong foundation in pediatrics and subspecialization in oncology and infectious diseases. He earned his Board Exam in General Pediatrics in 1996, establishing his clinical foundation. His academic excellence and leadership were recognized in 2005, when he was awarded a Professorship at Johann Wolfgang Goethe University, Frankfurt, one of Germany’s leading medical institutions. That same year, he also earned a Diploma in Pediatric Infectious Diseases from the German Society for Pediatric Infectious Diseases, strengthening his expertise in managing complex infections. In 2007, he completed his Board Exam in Pediatric Hematology and Oncology, formally certifying his specialization in childhood cancers and blood disorders. Combined with his post-doctoral fellowship at the National Cancer Institute (NIH, USA), his education and training provided him with exceptional clinical and research competencies, which now serve as the foundation of his international reputation in pediatric oncology and infection medicine.

Experience

Dr. Lehrnbecher has cultivated an impressive career spanning over two decades in pediatric hematology and oncology. Since 2001, he has served as a Senior Consultant at Johann Wolfgang Goethe University, Frankfurt, providing expertise in pediatric cancer care and mentoring young clinicians. In 2018, he advanced to Head of the Division of Pediatric Hematology and Oncology, where he oversees patient care, clinical programs, and research initiatives. Earlier in his career, he worked as a Consultant at the Children’s Hospital, University of Würzburg (1999–2000), where he gained valuable clinical insights. A pivotal moment came during his post-doctoral fellowship at the National Cancer Institute, NIH, USA (1996–1999), under Dr. Stephen Chanock, where he developed a strong research focus on infections in immunocompromised children. His leadership in both clinical and research settings reflects his dedication to integrating science with practice, driving advancements in pediatric oncology, supportive care, and infection management worldwide.

Awards and Honors

Dr. Lehrnbecher’s contributions to pediatric oncology and infectious diseases have earned him numerous prestigious awards. In 2024, he received the Best Publication Award from the German Society of Mycology (DMykG), recognizing his impactful research. He previously won the Kind Philipp Award from the German Society of Pediatric Oncology and Hematology (GPOH) and the Poster Award from the International Society of Pediatric Oncology (SIOP). His groundbreaking work in mycology earned him the Outstanding Research in Mycology Award, while his contributions to histiocytic disorders were honored with the Nesbit Award from the Histiocyte Society. Earlier in his career, he was recognized with the Outstanding Research Award in Novel Therapeutic Strategies by the Children’s Cancer Foundation Mainz and the Educational Grant from the German Foundation of Cancer Aid. Collectively, these awards highlight his sustained excellence in clinical care, medical research, and innovation.

Research Focus

Dr. Lehrnbecher’s research is centered on improving the management of infections in immunocompromised pediatric patients, particularly those undergoing cancer treatment or hematopoietic stem cell transplantation. He has extensively studied antifungal prophylaxis, bacterial infections, and novel diagnostic markers for invasive fungal disease in children. His investigations aim to refine supportive care strategies, reduce infection-related mortality, and improve the quality of life for pediatric cancer patients. A particular focus of his research has been the efficacy of antifungal and antibiotic therapies, as well as the development of evidence-based guidelines for infection management. Beyond infectious diseases, his work also contributes to optimizing cancer treatment protocols, including long-term maintenance therapies for pediatric sarcomas. Through clinical trials, prospective studies, and international collaborations, Dr. Lehrnbecher has made significant advances in pediatric oncology. His contributions are widely recognized for bridging research and practice, helping set global standards for supportive care in children with cancer.

Publications

  • Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients.

  • Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation.

  • Pediatric Patients with Stage IV Rhabdomyosarcoma Benefit from Long-Term Maintenance Therapy: CWS Trials Results.

  • Serum Beta-D-Glucan in the Diagnosis of Invasive Fungal Disease in Children: A Critical Analysis.

  • Cerebrospinal Fluid System Infection in Children with Cancer: A 14-Year Retrospective Analysis.

  • Infections during Non-Neutropenic Episodes in Pediatric Cancer Patients: A Prospective European Study.

Conclusion

Dr. Thomas Lehrnbecher is an internationally recognized leader in pediatric oncology and infectious diseases. His pioneering research, clinical leadership, and commitment to advancing supportive care in childhood cancer treatment have transformed patient outcomes worldwide. His achievements and continued impact make him a highly deserving candidate for the Medicine Award, symbolizing excellence in medical research and clinical innovation.

Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Published on by Academic Excellence

Prof. Dr. Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Prof. Dr. Inamul Hasan Madar | Medicine | Yenepoya Universtiy |India

Dr. Inamul Hasan Madar is a distinguished researcher and educator in the field of biochemistry with a specialization in oncology proteogenomics. He earned his PhD from Korea University, a globally ranked institution, and has since developed extensive expertise in cancer genomics, multiomics integration, and bioinformatics. With a strong commitment to advancing medical research, Dr. Madar has served as an adjunct faculty at Saveetha Medical College (SIMATS), where he has mentored PhD, MD, MBBS, and MSc students in cutting-edge biomedical sciences. His international research experience includes appointments at Korea University and Hanyang University in South Korea, where he contributed to high-impact oncology projects. As Director and Lead of Canary Oncoceutics India, he has bridged the gap between research and industry by leading innovative onco-therapeutic initiatives. Widely published in top-tier journals, Dr. Madar has also served as a reviewer for international journals and as a member of prestigious scientific societies worldwide.

Author profile

Orcid

Education

Dr. Madar’s academic journey reflects a deep pursuit of excellence in biomedical sciences. He earned his PhD in Biochemistry, specializing in Onco-Proteogenomics, from Korea University, Seoul, ranked among the top global universities. His doctoral work focused on proteogenomic profiling and cancer biomarker discovery, positioning him at the forefront of precision oncology. Before this, he pursued advanced training in bioinformatics, molecular biology, and proteomics, equipping him with multidisciplinary skills to tackle complex biomedical challenges. His postgraduate education emphasized molecular diagnostics and computational approaches, while his undergraduate studies laid the foundation in biochemistry and clinical applications. Dr. Madar has also completed specialized training programs in next-generation sequencing (NGS), computational modeling, molecular docking, and drug discovery pipelines. Furthermore, he has been actively engaged in faculty development programs, including pedagogy training for undergraduate teaching in life sciences and biotechnology. This comprehensive educational background underscores his ability to combine research innovation with academic excellence.

Experience

Dr. Madar’s professional experience spans academia, research, and industry. He currently serves as Adjunct Faculty at Saveetha Medical College, SIMATS, where he mentors MBBS, MD, MSc, MPhil, and PhD students in research methodologies, cancer biology, and bioinformatics. He is also Director and Lead (Marketing) at Canary Oncoceutics India, overseeing translational oncology research and innovation in oncoceutical product development. Internationally, he worked as a Visiting Scientist at Korea University, specializing in proteogenomics, and as a Researcher at Hanyang University, Seoul, in bioengineering. In India, his previous roles include Scientist & Course Coordinator at Biocuration, where he designed genomics and drug development modules, and Junior Scientist at iPro Technologies. He has also contributed as a guest lecturer at Bharathidasan University, training future biochemists. His expertise extends to designing computational pipelines, analyzing multiomics datasets, and leading cross-disciplinary projects that bridge laboratory science and clinical application, particularly in cancer therapeutics and biomarker discovery.

Awards and Honors

Dr. Inamul Hasan Madar has received widespread recognition for his contributions to biomedical research and education. His publications in high-impact journals such as Nature Cancer, Oncotarget, Briefings in Bioinformatics, and Molecular Cancer have positioned him among leading voices in proteogenomics and cancer research. He has served as a peer reviewer for several prestigious journals, including Nature’s Scientific Reports, Frontiers in Oncology, BMC Medical Genomics, and Journal of Translational Medicine. He has been actively involved in international professional societies, including the American Association of Cancer Research (AACR), American Society for Biochemistry and Molecular Biology (ASBMB), International Society of Computational Biology (ISCB), and South African and Korean Mass Spectrometry Societies. His leadership roles include serving as Vice President of ISCB-RSG India, demonstrating his dedication to strengthening scientific networks. He has also mentored numerous graduate and medical students, guiding them to publish impactful research, file patents, and develop translational medical applications.

Research Focus

Dr. Madar’s research focus lies at the intersection of cancer genomics, proteogenomics, and computational biology. He specializes in integrating multiomics datasets to identify novel biomarkers and therapeutic targets for treatment-resistant cancers, particularly cervical, prostate, and oral squamous cell carcinoma. His expertise in next-generation sequencing (RNA-Seq, Exome-Seq) and bioinformatics has enabled him to develop innovative pipelines for cancer biomarker discovery, molecular subtyping, and clinical variant interpretation. Beyond oncology, he has contributed to research in neurobiology, metabolic disorders, cardiovascular protection, and bioactive peptides against diabetes and obesity. His translational approach emphasizes the “bench-to-bedside” concept, applying computational models and molecular profiling to guide precision medicine strategies. Dr. Madar has also explored theranostic targets, signaling networks, and novel oncoceutical formulations. His interdisciplinary collaborations with international research groups have advanced drug design, CAR-T therapy applications, and personalized treatment strategies, positioning him as a pioneer in cancer research and translational medicine.

Publications

  • Correction to: Proteogenomic characterization of molecular and cellular targets for treatment-resistant cervical cancers.

  • Molecular analysis of HPV16 and HPV18 oncogenes in oral squamous cell carcinoma.

  • Proteogenomic characterization of treatment-resistant subtypes in cervical cancers.

  • Theranostic Target NSUN2 uncovered with systematic assembly of 805 datasets.

  • Unravelling the phosphoregulatory network of PKC-delta (PKC-δ).

  • BDNF-TrkB signalling: A neurotrophic pathway to cardiovascular protection.

  • Physiological activities of bioactive peptides against diabetes and obesity.

  • SGLT2 inhibitors as dual therapeutic targets for cardiovascular and renal health.

  • Biobased nanomaterials and rhizobacteria for sustainable plant growth.

  • CAR-T therapy in oral squamous cell carcinoma: Current innovations and future prospects.

Conclusion

Dr. Inamul Hasan Madar exemplifies excellence in translational medicine, combining cutting-edge cancer research with dedicated academic mentorship. His impactful publications, international collaborations, and leadership in oncology research position him as a transformative figure in biomedical sciences. Through his expertise in proteogenomics and bioinformatics, he continues to advance precision medicine while inspiring the next generation of medical researchers.

Afra Wasama Islam | Medicine | Academic Excellence Award

Published on by Academic Excellence

Ms. Afra Wasama Islam | Medicine | Academic Excellence Award

Ms. Afra Wasama Islam | Medicine | Faculty of Medicine, Tbilisi State Medical University | Georgia

Afra Wasama Islam is a dedicated 5th-year medical student at Tbilisi State Medical University, Georgia, with a strong passion for clinical practice and medical research. She combines technical proficiency in clinical examination, surgical skills, and pharmacotherapy with advanced competencies in wet lab techniques such as ELISA, PCR, and microscopy. As the Chief Executive Officer of ClinNova International, Afra leads a team of over 70 individuals, demonstrating her leadership and management expertise alongside her academic achievements. She actively contributes to global medical communities through her involvement in research clubs, webinars, workshops, and scientific presentations. With publications in international journals and recognition for her work on gastrointestinal health, infectious diseases, and cardiovascular research, she is establishing herself as a promising medical researcher. Her diverse interests, multilingual abilities, and strong creative outlook further complement her vision of advancing healthcare research and practice on a global scale.

Author Profile

Orcid

Education 

Afra Wasama Islam is pursuing her Bachelor of Medicine, Bachelor of Surgery (MBBS) at Tbilisi State Medical University, Georgia, where she is currently in her 5th year of studies (2021–2027). Her academic journey reflects a strong commitment to excellence in both theoretical knowledge and hands-on training. She has acquired comprehensive exposure to medical history-taking, clinical examinations, pharmacotherapy, and advanced surgical procedures. Afra has further strengthened her academic foundation through certifications in Good Clinical Practice (GCP), NIH’s IPPCR course, Basic Surgical Skills, Basic and Pediatric Advanced Life Support, and Healthcare Communication. These achievements demonstrate her dedication to maintaining high standards in medical ethics, patient care, and research methodologies. Her education is also enriched by global exposure, as she participates in international webinars, workshops, and presentations, gaining cross-cultural medical perspectives. With her academic rigor and continuous learning, Afra is well-prepared to contribute significantly to clinical medicine and research innovation.

Experience

Afra’s professional experience highlights her dual strengths in clinical research and leadership. As the CEO of ClinNova International, she manages and mentors a team of 70+, leading global collaborations in medical research. She also serves as a Research Mentor at ClinAcademy and ClinNova International, nurturing future medical researchers. Her leadership extends to positions such as Head of the Creative Department at GCMER Georgia, Co-Head of Workshops at IJCR, and Secretary of the Social Media Chapter at YCC, where she has supervised and trained diverse teams. Afra has actively contributed to academic communities as a Webinar Host for SSSG and a Core Team member of the Research Club at TSMU. Beyond management, she has presented her research at multiple international conferences, covering topics from oncology to robotic surgery. This blend of organizational leadership, clinical knowledge, and academic research positions her as a versatile and impactful emerging medical professional.

Awards and Honors 

Afra Wasama Islam has been recognized for her academic excellence and scientific contributions through various awards and honors. She has presented her research at prestigious platforms such as Eternity (Tbilisi, Georgia), Pulmora, and the Royal Society of Medicine (UK), where her work on topics including lung cancer surgery, spinal cord injury, robotic mastectomy, and stroke prevention has gained significant attention. Her oral and poster presentations reflect her dedication to advancing clinical understanding and innovative practices in medicine. She has also been honored with leadership responsibilities across organizations like ClinNova International, IJCR, and GCMER, highlighting her role as a young leader in medical research. Afra’s certifications from renowned institutions, including the National Institute of Health (NIH) and Clinical Skills Centers, further reinforce her credibility. Her professional memberships with international medical societies showcase her global recognition and commitment to collaborative medical advancement.

Research Focus 

Afra Wasama Islam’s research focus integrates clinical medicine, public health, and translational science. She has explored diverse areas such as neuropsychiatric disorders (Depersonalization-Derealization Disorder), gastrointestinal health (FODMAP diets in IBS patients), and infectious diseases (human metapneumovirus and measles). Her cardiovascular research investigates the implications of L-carnitine and TMAO in heart complications, while her public health studies address zoonotic viral transmission and healthcare strategies. Beyond disease mechanisms, Afra is passionate about digital health, demonstrated in her work on smart inhalers for asthma and COPD, combining medicine with technological innovation. She has also contributed to research on surgical innovations, including robotic versus open mastectomy and thoracotomy versus minimally invasive surgery. This diverse portfolio reflects her forward-looking vision of bridging clinical practice, research, and digital healthcare solutions. With her strong multidisciplinary foundation, Afra aims to contribute to patient-centered healthcare, medical innovation, and global public health improvement.

Publications 

  1. Depersonalization-Derealization Disorder: Etiological Mechanism, Diagnosis and Management.

  2. Comparison of Impact of High vs. Low FODMAP Diet on Gut Flora in IBS Patients.

  3. Clinical Implications of L-Carnitine and Elevated TMAO in Cardiovascular Complications.

  4. Clinical Insights in Human Metapneumovirus Management and Prognosis.

  5. Potential Zoonotic Transmission of HKU5-CoV-2: Host Susceptibility & Public Health Risks.

  6. Comprehensive Review of Measles: Outbreaks, Clinical Manifestations & Therapies.

Conclusion

Afra Wasama Islam exemplifies the qualities of a future leader in medicine combining clinical acumen, innovative research, and effective leadership. With her international publications, research presentations, and executive experience in medical organizations, she has established herself as a promising young professional. Her focus on integrating clinical practice, research, and digital health innovation positions her to make impactful contributions to global healthcare. She is highly suitable for recognition under the Medicine Award, as her work reflects both academic excellence and dedication to advancing human health.